Incidence of hepatocellular carcinoma in a thalassemia unit

Hemoglobin

Volumn 34, Issue 3, 2010, Pages 221-226

  Fragatou, Soso ^a   Tsourveloudis, Ioannis ^a   Manesis, George ^b  

^a Gennimatas Hospital   (Greece)

^b Ippokration Genereal Hospital   (Greece)

Author keywords

Chelating agents; Cirrhosis; Hepatitis C and B virus(es) (HCV and HBV); Hepatocellular carcinoma; Iron overload; Thalassemia

Indexed keywords

ANTINEOPLASTIC AGENT; DEFEROXAMINE; HEPATITIS C ANTIBODY; INTERFERON; IRON; PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BETA THALASSEMIA; CANCER INCIDENCE; CHELATION THERAPY; CHEMOEMBOLIZATION; CONFERENCE PAPER; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; IRON CHELATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HEMOSIDEROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RISK FACTOR; THALASSEMIA MAJOR; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES; CARCINOMA, HEPATOCELLULAR; CHELATION THERAPY; DEFEROXAMINE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; IRON; IRON CHELATING AGENTS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; THALASSEMIA;

CERCOPITHECINE HERPESVIRUS 1; HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 77953245415     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2010.485071     Document Type: Conference Paper

References (17)

1. Brown DB, ChapmanWC, Cook RD, et al. Chemoembolization of hepatocellular carcinoma: Patient status at presentation and outcome over 15 years at a single center. Am J Roentgenol. 2008;190(3):608-615.
2. Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary haemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 2001;33(3):647-651.
3. Mancuso A, Sciarrino E, Penda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin. 2006;30(1):119-124.
4. Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124(1):114-117.
5. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL Conference. J Hepatol. 2001;35(3):421-430.
6. Velazquez RF, Rodriguez M, Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003;37(3):520-527. (Pubitemid 36258772)
7. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36(5, Suppl. 1):574-583.
8. Bruix J, Calvet X, Costa J, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 1989:2(8670):1004-1006.
9. Trinchet JC, Ganne-Carrie N, Nahon P, N'Kontchou G, Beaugrand M. Hepatocellular carcinoma in patients with hepatitis C virus related chronic liver disease. World J Gastroenterol. 2007;13(17):2455-2460.
10. Deugnier YM, Guyader D, Crantock L, Primary liver cancer in genetic hemochromatosis: a clinical, pathological and pathogenetic study of 54 cases. Gastroenterology. 1993;104(1):228-234.
11. Hann HWL, Stahlhut MW, Rubin R, Maddrey WC. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer. 1992;70(8):2051-2056.
12. Tabor E, Kim CM. Inhibition of human hepatocellular carcinoma and hepatoblastoma cell lines by deferoxamine. J Med Virol. 1991;34(1):45-50.
13. Bacon BR, Britton RS. Hepatic injury in chronic iron overload; role of lipid peroxidation. Chem Biol Interact. 1989;70(3-4):183-226.
14. Britton RS. Metal-induced hepatotoxicity. Semin Liver Dis. 1996;16(1):3-12.
15. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Rilli A, et al. Usefulness of fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23(2):1747-1753.
16. Tangkijvanich P, Anukulkarnkusol W, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum α-fetoprotein levels. J Clin Gastroenterol. 2000;31(4):302-308.
17. Ambu R, Crisponi G, Sciot R, Uneven hepatic iron and phosphorus distribution in β-thalassemia. J Hepatol. 1995;23(5):544-549.